March 26th, 2010
 |
| “Almost all women with osteoporosis are over the age of 65 to 84 and 93% are unaware of their condition until they are officially diagnosed.” |
Postmenopausal women receiving estrogen therapy may experience problems with alkaline phosphatase and Osteoporosis. Lowered levels of alkaline phosphatase can also indicate protein deficiency, magnesium deficiency, too much vitamin D or too little vitamin C, or poor nutrition.
Osteoporosis is a progressive condition of bone loss which can lead to an increased risk of fractures and chronic pain in the bones. Almost all women with osteoporosis are over the age of 65 to 84 and 93% are unaware of their condition until they are officially diagnosed.
Alkaline phosphatase and osteoporosis are related to bone resorption. Alkaline phosphatases are a group of enzymes typically found in the liver and bone. The enzymes operated by splitting off phosphorus (acidic mineral) creating an alkaline pH. This relationship of alkalinity to bone development helps with the prevention and reversal of osteoporosis.
In a recent study, researchers observed 35 postmenopausal women with osteoporosis during their first year of treatment with the anti-resorptive drug, alendronate. Before taking the prescription drug, the women were within the typical postmenopausal ranges of protein mass and alkaline phosphatase activity. Researchers noticed the decline in alkaline phosphatase reached a plateau after six months.
For more information on treating low levels of Alkaline Phosphatase and Osteoporosis, visit http://www.orderonlinedrugs.com
